Publications et communications

Communications & Publications 2020–2025

Communications & Publications

2025

Publications

  1. Le Rochais M, Morvan M, Bouzeloc S, Nousbaum JB, Guillard M, Le Noac’h P, Garaud S, Uguen A. A tertiary lymphoid structures-based pathological score predicts survival and recurrence in colorectal cancer patients. Immunobiology. 2025;230(3):152911. doi:10.1016/j.imbio.2025.152911. PMID:40398138.
  2. Goebel G, Jooste V, Molinie F, Grosclaude P, Woronoff AS, Alves A, Bouvier V, Nousbaum JB, Plouvier S, Bengrine-Lefevre L, Rabel T, Bouvier AM; FRANCIM Network. Surgical patterns of care of pancreatic cancer: a French population-based study. Eur J Surg Oncol. 2025;51(8):108748. doi:10.1016/j.ejso.2024.108748. PMID:39419745.

2024

Communications

  1. Chaigneau T, Dejardin O, Nguyen TTN, Bouvier AM, Gardy J, Molinié F, Nousbaum JB, Tron L, Alves A, Launoy G, Bouvier V, Ollivier-Hourmand I. Influence de l’accès aux soins et de l’environnement socio-économique sur la survie des patients atteints de carcinome hépatocellulaire et de cholangiocarcinome intra-hépatique. JFHOD; 14–17 mars 2024; Paris. Communication orale.
  2. Debuc Y, Morvan M, Canévet M, Brousse-Potocki J, Kermarrec T, Bouzeloc S, Robaszkiewicz M, Reboux N, Quénéhervé L, Nousbaum JB. Analyse et survie des patients atteints d’un cancer colorectal selon le motif d’exclusion du dépistage organisé (2016–2019). JFHOD; 14–17 mars 2024; Paris. Poster.
  3. Kermarrec M, Robaszkiewicz M, Morvan M, Bideau K, Edeline J, Brousse-Potocki J, Grasset D, Lambert S, Metges JP, Langlois A, Pourchasse C, Desgrippes R. Conséquence de la Covid-19 sur la prise en charge des patients atteints de cancer colorectal en Bretagne. JFHOD; 14–17 mars 2024; Paris. Poster.

Publications

  1. Gardy J, Wilson S, Guizard AV, Bouvier V, Launay L, Alves A, Bara S, Bouvier AM, Coureau G, Cowppli-Bony A, Dabakuyo Yonli S, Daubisse-Marliac L, Defossez G, Hammas K, Hure F, Jooste V, Lapotre-Ledoux B, Nousbaum JB, Plouvier S, Seigneurin A, Tretarre B, Vigneron N, Woronoff AS, Launoy G, Molinie F, Bryere J, Dejardin O. Access to primary care and mortality in excess for patients with cancer in France: results from 21 registries. Cancer. 2024;130(23):4096–4108. doi:10.1002/cncr.35519. PMID:39163260.
  2. Comoz B, Ollivier-Hourmand I, Bouvier AM, Nousbaum JB, Nguyen TTN, Launoy G, Bouvier V, Bryere J. Impact of socio-economic environment on incidence of primary liver cancer in France between 2006 and 2016. Liver Int. 2024;44(2):446–453. doi:10.1111/liv.15784. PMID:38010978.
  3. Toudic HP, Morvan M, Reboux N, Chaussade S, Gronier O, Koch S, Bernardini D, Coron E, Robaszkiewicz M, Quénéhervé L. Expansion of interventional endoscopy and day-case procedures: a nationwide longitudinal study of gastrointestinal endoscopy in France. Clin Res Hepatol Gastroenterol. 2024;49(1):102505. doi:10.1016/j.clinre.2024.102505. PMID:39608706.
  4. Sant M, Vener C, Lillini R, Rossi S, Bonfarnuzzo S, Marcos-Gragera R, Maynadié M, Innos K, Paapsi K, Visser O, Bernasconi A, Demuru E, Di Benedetto C, Mousavi SM, Blum M, Went P, Serraino D, Bennett D, Sánchez MJ, De Angelis R; EUROCARE-6 Working Group. Long-term survival for lymphoid neoplasms and national health expenditure (EUROCARE-6). Lancet Oncol. 2024;25(6):731–743. doi:10.1016/S1470-2045(24)00141-4. PMID:38703784.
  5. Botta L, Capocaccia R, Bernasconi A, Rossi S, Galceran J, Maso DL, Lepage C, Molinié F, Bouvier AM, Marcos-Gragera R, Vener C, Guevara M, Murray D, Ragusa R, Gatta G, Jooste V; EUROCARE-6 Working Group. Estimating cure and risk of death from other causes: EUROCARE-6 data. Eur J Cancer. 2024;208:114187. doi:10.1016/j.ejca.2024.114187. PMID:39013266.
  6. Bouvier AM, Jooste V, Lillini R, Marcos-Gragera R, Katalinic A, Giorgi Rossi P, Launoy G, Bouvier V, Guevara M, Ardanaz E, Rapiti Aylward E, Innos K, Barranco MR, Sant M; European High Resolution Working Group on Colorectum. Differences in survival and recurrence of colorectal cancer by stage across European registries. Int J Cancer. 2024;155(5):807–815. doi:10.1002/ijc.34944. PMID:38577898.
  7. Jooste V, Grosclaude P, Defossez G, Daubisse L, Woronoff AS, Bouvier V, Chirpaz E, Tretarre B, Lapotre B, Plouvier S, Launoy G, Bonneault M, Molinié F, Bouvier AM; FRANCIM Network. Net survival in colon and rectal cancer by stage according to neoadjuvant treatment: a French population-based study. Dig Liver Dis. 2024;56(6):1064–1070. doi:10.1016/j.dld.2023.10.012. PMID:37926634.

2023

Communications

  1. Comoz B, Bryere J, Bouvier AM, Nousbaum JB, Launoy G, Bouvier V, Ollivier-Hourmand I. Disparités socio-économiques et incidence du cancer primitif du foie (2006–2016). JFHOD; 16–19 mars 2023; Paris. Communication orale.
  2. Nguyen TTN, Dejardin O, Bouvier AM, Nousbaum JB, Molinié F, Gardy J, Launoy G, Bouvier V, Ollivier-Hourmand I. Inégalités socio-économiques et survie des cancers primitifs du foie. JFHOD; 16–19 mars 2023; Paris. Communication orale.
  3. Corbel T, Morvan M, Bouzeloc S, Kermarrec T, Nousbaum JB, Le Reste JY, Reboux N, Quénéhervé L, Robaszkiewicz M. Distribution des kits par pharmaciens et performance du dépistage organisé du cancer colorectal : étude de population. JFHOD; 16–19 mars 2023; Paris. Poster.

Publications

  1. Badic B, Morvan M, Quénéhervé L, Bouzeloc S, Kermarrec T, Nousbaum JB, Reboux N. Real world data for pancreatic adenocarcinoma from a population-based study in France. Cancers (Basel). 2023;15(2):525. doi:10.3390/cancers15020525. PMID:36672474.
  2. Thobie A, Bouvier AM, Bouvier V, Jooste V, Quenéhervé L, Nousbaum JB, Alves A, Dejardin O. Survival variability across hospitals after resection for pancreatic adenocarcinoma: a multilevel survival analysis. Eur J Surg Oncol. 2023;49(8):1450–1456. doi:10.1016/j.ejso.2023.03.228. PMID:37055280.
  3. Canévet M, Pruvost-Couvreur M, Morvan M, Badic B, Brousse-Potocki J, Kermarrec T, Bouzeloc S, Nousbaum JB, Robaszkiewicz M, Reboux N, Quénéhervé L. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population. Clin Res Hepatol Gastroenterol. 2023;47(3):102093. doi:10.1016/j.clinre.2023.102093. PMID:36764389.
  4. Matz M, Valkov M, Šekerija M, Luttman S, Caldarella A, Coleman MP, Allemani C; CONCORD Working Group. Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000–2014 (CONCORD-3). Cancer Commun (Lond). 2023;43(9):963–980. doi:10.1002/cac2.12457. PMID:37488785.
  5. Nikšić M, Minicozzi P, Weir HK, Zimmerman H, Schymura MJ, Rees JR, Coleman MP, Allemani C; US CONCORD Working Group. Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD-3 study. Cancer Commun (Lond). 2023;43(1):87–99. doi:10.1002/cac2.12375. PMID:36353792.
  6. Tron L, Remontet L, Fauvernier M, Rachet B, Belot A, Launay L, Merville O, Molinié F, Dejardin O, Francim Group, Launoy G. Is the social gradient in net survival observed in France the result of inequalities in cancer-specific mortality or inequalities in general mortality? Cancers (Basel). 2023;15(3):659. doi:10.3390/cancers15030659. PMID:36765616.
  7. Demuru E, Rossi S, Ventura L, Dal Maso L, Guzzinati S, Katalinic A, Lamy S, Jooste V, Di Benedetto C, De Angelis R; EUROCARE-6 Working Group. Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes. Front Oncol. 2023;13:1114701. doi:10.3389/fonc.2023.1114701. PMID:37168378.

2022

Communications

  1. Canevet M, Pruvost-Couvreur M, Badic B, Brousse-Potocki J, Le Reun S, Kermarrec T, Bouzeloc S, Nousbaum JB, Robaszkiewicz M, Reboux N, Quénéhervé L. Sensitivity of faecal immunochemical test for colorectal cancer screening and risk factors for interval cancer: a French population-based study. ESGE Days 2022; Prague. Communication orale.
  2. Gieu M, Pruvost-Couvreur M, Kermarrec T, Bouzeloc S, Reboux N, Poureau PG, Metges JP, Robaszkiewicz M, Nousbaum JB, Quénéhervé L. Facteurs associés à la non-présentation en RCP des patients atteints d’un cancer de l’œsophage, de la JOG et de l’estomac. JFHOD 2022; Paris. Poster.
  3. Canevet M, Pruvost-Couvreur M, Kermarrec T, Bouzeloc S, Brousse-Potocki J, Le Reun S, Badic B, Nousbaum JB, Robaszkiewicz M, Reboux N, Quénéhervé L. Sensibilité du test immunologique fécal pour le dépistage du CCR et risque de cancer d’intervalle. JFHOD 2022; Paris. Poster.

Publications

  1. Reboux N, Jooste V, Goungounga J, Robaszkiewicz M, Nousbaum JB, Bouvier AM. Incidence and survival in synchronous and metachronous liver metastases from colorectal cancer. JAMA Netw Open. 2022;5(10):e2236666.
  2. Badic B, Bouvier AM, Bouvier V, Morvan M, Jooste V, Alves A, Nousbaum JB, Reboux N. Predictors of survival in elderly patients with metastatic colon cancer: a population-based cohort study. Cancers (Basel). 2022;14(21):5208.
  3. Mulliri A, Gardy J, Cariou M, Launoy G, Robaszkiewicz M, Alves A, Bouvier V, Dejardin O. Care management and survival of patients diagnosed with synchronous metastatic colorectal cancer: a population-based study. Cancers (Basel). 2022;14(7):1777.
  4. Thomas F, Bouvier AM, Cariou M, Bouvier V, Jooste V, Pouchucq C, Gardy J, Quénéhervé L, Launoy G, Alves A, Eid Y, Dejardin O. Influence of non-clinical factors on restorative rectal cancer surgery. Dig Liver Dis. 2022;54(2):258–267.
  5. Reboux N, Cadieu E, Pruvost-Couvreur M, Cariou M, Kermarrec M, Kermarrec T, Bouzeloc S, Nousbaum JB, Robaszkiewicz M, Quénéhervé L. Factors associated with non-presentation in a multidisciplinary team meeting for colon cancer. Clin Res Hepatol Gastroenterol. 2022;46(8):101950.
  6. Aujoulat P, Le Goff D, Dany A, Robaszkiewicz M, Nousbaum JB, Derriennic J, Cariou M, Guillou M, Le Reste JY. Improvement of participation rate in CRC screening by training GPs in motivational interviewing (AmDepCCR). Trials. 2022;23(1):144.
  7. Cardoso R, Guo F, Heisser T, De Schutter H, Van Damme N, Nilbert MC, Christensen J, et al. Overall and stage-specific survival of patients with screen-detected colorectal cancer in Europe. Lancet Reg Health Eur. 2022;21:100458.
  8. Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard JL, et al; CONCORD Working Group. Worldwide trends in survival for leukaemia in children, adolescents, and young adults (2000–14). Lancet Child Adolesc Health. 2022;6(6):409–431.

2021

Communications

  1. Pruvost-Couvreur M, Kermarrec M (OncoBretagne). Étude de l’exhaustivité de la présentation en RCP pour le cancer du côlon : étude collaborative. Congrès National des Réseaux de Cancérologie; sept. 2021. Communication orale.
  2. Garcia GA, Cariou M, Reboux N, Kermarrec T, Bouzeloc S, Robaszkiewicz M, Quénéhervé L, Nousbaum JB. Survie des patients atteints de cholangiocarcinome intra-hépatique (2005–2017). JFHOD; 18–21 mars 2021; Paris. Communication orale.
  3. Bouvier AM, Uhry Z, Bouvier V, Cariou M, Robaszkiewicz M, Remontet L, Coureau G, Tretarre B. Long term colorectal cancer survival in France : population-based study. 45e GRELL; 12–14 mai 2021; Luxembourg. Communication orale.
  4. Gaye E, Cariou M, Bore P, Poureau PG, Bouzeloc S, Doucet L, Jestin-Letallec V, Bideau K, Thereaux J, Robaszkiewicz M, Metges JP. Survie des carcinomes épidermoïdes de l’œsophage et de la JOG métastatiques (2009–2018) – ESPErE. JFHOD; mars 2021. Poster.
  5. Bore P, Cariou M, Gaye E, Bouzeloc S, Nousbaum JB, Robaszkiewicz M, Jestin-Letallec V, Bideau K, Thereaux J, Poureau PG, Metges JP. HEROIC – Attitudes thérapeutiques et tolérance des adénocarcinomes œsogastriques HER2+. JFHOD; mars 2021. Poster.
  6. Thomas Q, Cariou M, Quénéhervé L, Kermarrec T, Kermarrec M, Bouzeloc S, Robaszkiewicz M, Nousbaum JB, Reboux N. Exhaustivité de la présentation en RCP des carcinomes hépatocellulaires (2014–2016). JFHOD; mars 2021. Poster.
  7. Cadieu E, Cariou M, Kermarrec M, Bouzeloc S, Reboux N, Nousbaum JB, Robaszkiewicz M, Quénéhervé L. Exhaustivité de la présentation en RCP des cancers du côlon (2014–2016). JFHOD; mars 2021. Poster.

Publications

  1. Badic B, Oguer M, Cariou M, Kermarrec T, Bouzeloc S, Nousbaum JB, Robaszkiewicz M, Quénéhervé L. Ostomy prevalence and survival in elderly patients with stage III and IV rectal cancer. Geriatr Gerontol Int. 2021;21(8):670–675.
  2. Badic B, Oguer M, Cariou M, Kermarrec T, Bouzeloc S, Nousbaum JB, Robaszkiewicz M, Quénéhervé L. Prognostic factors for stage III colon cancer in patients ≥80 years. Int J Colorectal Dis. 2021;36(4):811–819.
  3. Castillon M, Kammerer-Jacquet SF, Cariou M, Costa S, Conq G, Samaison L, Douet-Guilbert N, Marcorelles P, Doucet L, Uguen A. FISH must be preferred to pan-TRK IHC for NTRK3-rearranged GIST. Appl Immunohistochem Mol Morphol. 2021;29(8):626–634.
  4. Bocciarelli C, Caumont C, Samaison L, Cariou M, Aline-Fardin A, Doucet L, Roudié J, Terris B, Merlio JP, Marcorelles P, Cappellen D, Uguen A. MSI-high RAS-BRAF wt colorectal adenocarcinomas with MLH1 loss harbor frequent targetable fusions. Hum Pathol. 2021;114:99–109.
  5. Cardoso R, Guo F, Heisser T, Hackl M, et al. CRC incidence, mortality, and stage distribution in Europe in the screening era. Lancet Oncol. 2021;22(7):1002–1013.
  6. Defossez G, Uhry Z, Delafosse P, Dantony E, et al; FRANCIM. Cancer incidence and mortality trends in France (1990–2018). BMC Cancer. 2021;21:726.
  7. Bouvier AM, Jooste V, Sanchez-Perez MJ, et al; Working Group on Colorectum. Management and survival of metastatic colorectal cancer in Europe. Dig Liver Dis. 2021;53(5):639–645.
  8. Girardi F, Rous B, Stiller CA, et al; CONCORD Working Group. Histology of brain tumors (2000–2014): a global population-based study. Neuro Oncol. 2021;23(10):1765–1776.
  9. Tron L, Fauvernier M, Bouvier AM, Robaszkiewicz M, Bouvier V, Cariou M, Jooste V, Dejardin O, Remontet L, Alves A, FRANCIM Group, Molinié F, Launoy G. Socioeconomic environment and survival in digestive cancers. Cancers (Basel). 2021;13(20):5156.
  10. Bouvier V, Cariou M, Bouvier AM, Nousbaum JB, Lecoffre C, de Brauer C, et al. Survie des personnes atteintes de cancer en France métropolitaine 1989–2018 — Vésicule et voies biliaires. INCa; 2021.

2020

Communications

  1. Drouet d’Aubigny A, Cariou M, Cholet F, Jezequel J, Arnachellum R, Risson JR, Hébert T, Nonent M, Robaszkiewicz M, Nousbaum JB. Élaboration d’un score pronostique chez les malades ayant un obstacle biliaire néoplasique. JFHOD; 26–29 mars 2020; Paris. Communication orale.
  2. Cardoso R, Hackl M, Ihle P, De Schutter H, Van Damme N, Valerianova Z, et al. Trends in colorectal cancer incidence and stage distribution in Europe in the screening era. UEG Week; 10–14 oct. 2020; Amsterdam. Communication orale.
  3. d’Aubigny A, Cariou M, Cholet F, Jezequel J, Arnachellum R, Risson JR, Hébert T, Nonent M, Robaszkiewicz M, Nousbaum JB. Elaboration of a prognostic score in patients with malignant biliary obstruction. ESGE Days; 23–25 avr. 2020; virtuel. Poster. Endoscopy. 2020;52(S01):204. doi:10.1055/s-0040-1704635.

Publications

  1. Uhry Z, Chatignoux E, Dantony E, Colonna M, Roche L, Fauvernier M, Defossez G, Le Guyader-Peyrou S, Monnereau A, Grosclaude P, Bossard N, Remontet L; FRANCIM. Multidimensional penalized splines for incidence and mortality-trend analyses and validation of national cancer-incidence estimates. Int J Epidemiol. 2020;49(6):1762–1770.
  2. Bouvier AM, Robaszkiewicz M, Jooste V, Cariou M, Drouillard A, Bouvier V, Nousbaum JB; FRANCIM. Trends in incidence of small bowel cancer according to histology: a population-based study. J Gastroenterol. 2020;55(2):181–188.
  3. Bourhis A, De Luca C, Cariou M, Vigliar E, Barel F, Conticelli F, Marcorelles P, Nousbaum JB, Robaszkiewicz M, Samaison L, Badic B, Doucet L, Troncone G, Uguen A. Evaluation of KRAS, NRAS and BRAF mutational status and microsatellite instability in early colorectal carcinomas invading the submucosa (pT1): towards an in-house molecular prognostication for pathologists? J Clin Pathol. 2020;73(11):741–747.
  4. Cariou M, El Fettouhi A, Kermarrec T, Bommelaere F, Foll Y, Nousbaum JB, Robaszkiewicz M, Quénéhervé L. Comparative evaluation of two colorectal cancer screening campaigns using different faecal occult blood tests in a French area. Cancer Epidemiol. 2020;69:101839.
  5. « Survie des personnes atteintes de cancer en France métropolitaine (1989–2018) » — sites digestifs (œsophage — adénocarcinomes, œsophage — épidermoïdes et synthèse, estomac, côlon, rectum, côlon & rectum, anus, foie, pancréas). Boulogne-Billancourt : INCa; 2020.

Newsletters du Registre

Newsletter RTDF 2025 Nouveau
Télécharger (PDF)
Newsletter RTDF 2024
Télécharger (PDF)
Lettre d’information RTDF 2021
Télécharger (PDF)